| __timestamp | Arrowhead Pharmaceuticals, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 505679000 |
| Thursday, January 1, 2015 | 57410147 | 487656000 |
| Friday, January 1, 2016 | 41454452 | 660876000 |
| Sunday, January 1, 2017 | 31690298 | 874278000 |
| Monday, January 1, 2018 | 52968505 | 1431159000 |
| Tuesday, January 1, 2019 | 81048686 | 2386000000 |
| Wednesday, January 1, 2020 | 128874979 | 3137000000 |
| Friday, January 1, 2021 | 206342000 | 4181000000 |
| Saturday, January 1, 2022 | 297307000 | 5562000000 |
| Sunday, January 1, 2023 | 353188000 | 7630000000 |
| Monday, January 1, 2024 | 505870000 | 9748000000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Genmab A/S and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Genmab A/S has consistently outpaced Arrowhead Pharmaceuticals, with R&D expenses peaking at approximately $7.63 billion in 2023, a staggering 1,400% increase from 2014. In contrast, Arrowhead Pharmaceuticals has shown a steady growth, with a 1,500% increase, reaching around $506 million in 2024.
This data highlights Genmab's aggressive investment strategy, while Arrowhead's more gradual approach suggests a focus on sustainable growth. The missing data for Genmab in 2024 leaves room for speculation on future trends. As the biotech landscape evolves, these investment patterns will likely shape the industry's next breakthroughs.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Pfizer Inc. and Arrowhead Pharmaceuticals, Inc.
GSK plc or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Investment: Takeda Pharmaceutical Company Limited vs Arrowhead Pharmaceuticals, Inc.
Analyzing R&D Budgets: Genmab A/S vs Incyte Corporation
Genmab A/S vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Genmab A/S vs Apellis Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Genmab A/S and Evotec SE
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Arrowhead Pharmaceuticals, Inc. vs ImmunityBio, Inc.
R&D Spending Showdown: Arrowhead Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Research and Development Investment: Arrowhead Pharmaceuticals, Inc. vs Mesoblast Limited